Compare ABVX & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABVX | CRL |
|---|---|---|
| Founded | 2013 | 1947 |
| Country | France | United States |
| Employees | 67 | N/A |
| Industry | | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 8.3B |
| IPO Year | N/A | 1999 |
| Metric | ABVX | CRL |
|---|---|---|
| Price | $116.86 | $153.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 13 |
| Target Price | $128.42 | ★ $197.58 |
| AVG Volume (30 Days) | 698.3K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,857,601,000.00 |
| Revenue This Year | N/A | $2.11 |
| Revenue Next Year | $0.22 | $2.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.48 |
| 52 Week Low | $4.77 | $91.86 |
| 52 Week High | $148.83 | $228.88 |
| Indicator | ABVX | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 31.28 |
| Support Level | $106.37 | $145.97 |
| Resistance Level | $131.27 | $157.42 |
| Average True Range (ATR) | 5.21 | 7.22 |
| MACD | -0.67 | -0.07 |
| Stochastic Oscillator | 41.53 | 0.63 |
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.